BioSpace News Archive

Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health” or the “Company”) today announced the election of the eleven directors nominated at its 2020 annual meeting of shareholders held on April 28, 2020.

Auxly Cannabis Group Inc. (TSX.V - XLY) (OTCQX: CBWTF) (“Auxly” or the “Company”), a consumer packaged goods company in the cannabis products market, today released its fourth quarter and full year 2019 financial results.

Recce Pharmaceuticals Ltd, the company developing a new class of broad-spectrum synthetic antibiotics, reported its March 2020 quarter results and operational highlights.

Canadian Blood Services is proud to be part of CONCOR, a national clinical trial to test the safety and effectiveness of COVID-19 convalescent plasma as a possible treatment to help patients infected with the virus.

SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced the exercise of options under its 2018 Biomedical Advanced Research and Development Authority (BARDA) contract (“19C BARDA Contract”) worth a total of approximately $101.3 million for the procurement of oral TPOXX for the treatment of smallpox (tecovirimat).

Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced that it plans to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering.

4WEB Medical, an orthopedic device company focused on developing innovative implants utilizing its proprietary Truss Implant Technology™, announced today that following the company’s highest quarterly revenue to date in Q4 2019 it achieved its second highest quarterly revenue in the first quarter of 2020.

Sumitovant Biopharma Ltd. today announced that the journal Obstetrics & Gynecology has published three abstracts from Myovant Sciences detailing additional efficacy and safety findings from the Phase 3 LIBERTY 1 and 2 studies of relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) in women with heavy menstrual bleeding associated with uterine fibroids.

Teleflex Incorporated, a leading global provider of medical technologies for critical care and surgery, has been awarded group purchasing agreements for Central Venous Access and Arterial Access with Premier, effective July 1.

Wellgistics Wholesale has earned Drug Distributor reaccreditation from the National Association of Boards of Pharmacy® for another three-year term.